Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.

ABSTRACT:

Background

The optimal dose and fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes and degrees of cirrhosis. In this study, we aimed to verify the dose-survival relationship to optimize dose selection for treatment of HCC.

Methods

This multicenter retrospective study included 602 patients with HCC, treated with SBRT between January 2011 and March 2017. The SBRT dosage was classified into high dose, moderate dose, and low dose levels: SaRT (BED₁₀ ≥ 100 Gy), SbRT (EQD₂ > 74 Gy to BED₁₀ < 100 Gy), and ScRT (EQD₂ < 74 Gy). Overall survival (OS), progression-free survival (PFS), local control (LC), and intrahepatic control (IC) we

SUBMITTER: Su TS 

PROVIDER: S-EPMC8058965 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature